How can modeling best contribute to the assessment of secondary stroke prevention strategies?
Matchar
David B
DB
Samsa
Gregory P
GP
D003362:Cost-Benefit Analysis; D023381:Endpoint Determination; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008962:Models, Theoretical; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D020521:Stroke / Q000191:economics* / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors